Table 2.
Comparison between patients with ANL Ctrough ≥10.29ng/ml (high-exposure group) and <10.29ng/ml (low-exposure group).
| Characteristic | high-exposure group (n=30) | low-exposure group (n=22) | p values |
|---|---|---|---|
| Age (years, range) | 69 (48-81) | 65 (44-84) | 0.29 |
| Body weight (kg, range) | 58 (43-89) | 60 (41-80) | 0.242 |
| Body surface area (m2, range) | 1.61 (1.38-2.01) | 1.66 (1.40-1.94) | 0.824 |
| Sex | |||
| Male | 17 | 13 | 0.613 |
| Female | 13 | 8 | |
| Dosage | |||
| ≥10mg | 26 | 13 | 0.023 |
| 8mg | 4 | 9 | |
| Smoking history | |||
| Never | 12 | 11 | 0.473 |
| Current/former | 18 | 11 | |
| ECOG PS | |||
| ≤1 | 27 | 16 | 0.104 |
| ≥2 | 3 | 6 | |
| Histology | |||
| Adenocarcinoma | 17 | 14 | 0.613 |
| Squamous | 13 | 8 | |
| TNM stage | |||
| III stage | 9 | 9 | 0.414 |
| IV stage | 21 | 13 | |
| Driver alterations | |||
| No | 20 | 17 | 0.404 |
| Yes | 10 | 5 | |
| Number of metastases | |||
| >3 | 14 | 7 | 0.281 |
| ≤3 | 16 | 15 | |
| Efficacy of previous therapy | |||
| Yes | 27 | 21 | 0.466 |
| No | 3 | 1 | |
| Drug Interactions | |||
| Dexamethasone | 2 | 0 | 0.217 |
| Amlodipine | 4 | 2 | 0.636 |
| Nifedipine | 3 | 2 | 0.913 |
| losartan | 1 | 3 | 0.168 |
| Metformin | 4 | 3 | 0.975 |
| Insulin | 3 | 1 | 0.466 |
| Levothyroxine | 2 | 4 | 0.199 |
| Atorvastatin | 6 | 3 | 0.549 |
| Rosuvastatin | 3 | 5 | 0.209 |
ECOG, Eastern Cooperative Oncology Group; PS, performance status; TNM, tumor node metastasis.
Bold values indicate that the difference were statistically significant.